Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Antibiotics & Dysbiosis

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Antibiotic-induced gut dysbiosis can lead to several metabolic disturbances:

Reduced production of short-chain fatty acids

Disruption of bile acid metabolism

Impairment of intestinal barrier function

Chronic low-grade inflammation

These changes may result in fat accumulation, insulin resistance, and disrupted immune homeostasis.
Zhu et al. 2026 Front Microbiol 17: 1782016

While antibiotics are essential for combating bacterial infections, their broad-spectrum activity can also eradicate [beneficial gut microbes](brain://RJGYSyi4C…

References (Sources)

A MULTIPLICITY OF MICROBIOMES
Kelly et al. 2022 Science 376(6596): 932
Antibiotic perturbations to the gut microbiome
Fishbein et al. 2023 Nat Rev Microbiol 2023: 1-17
Review
Antibiotics modulate neoadjuvant therapy efﬁciency in patients with breast cancer: a pilot analysis
Zhang et al. 2021 Sci. Rep. 11: 14024
Implication of gut microbiota in the association between infant antibiotic exposure and childhood adiposity/obesity and adiposity accumulation
Chen et al. 2020n
Interaction between microbiota and immunity in health and disease
Zheng et al. 2020c Cell Res. 30: 492-506
Review
Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion
Byndloss et al., 2017 Science 357: 570
Phase II Clinical Trial for Prevention of Delayed Diarrhea with Cholestyramine/Levoﬂoxacin in the Second-Line Treatment with Irinotecan Biweekly in Patients with Metastatic Colorectal Carcinoma
Flieger et al. 2007 Oncology 72: 10-16

AI Chat

5/25/2026

Chat with our artificial intelligence:

Start chat!

Antibiotics & Dysbiosis

Welcome to meRfi-GM!

Navigation

Contents

References (Sources)

AI Chat